Cambrooke Therapeutics, Inc., an Ayer, Massachusetts-based global therapeutic nutrition company, closed its Series C funding round of undisclosed amount.
The round was led by Seventure Partners, investing out of its latest healthcare and nutrition focused Health For Life CapitalTM vehicle, with participation from Galen Partners (Stamford, Connecticut), as well as other co-investors from both Europe and the United States.
The company intends to use the funds to continue global expansion and entry into other disease states.
Founded in 2000 and led by CEO Howard Lossing, Cambrooke provides medical food products for people with phenylketonuria (PKU) via the Glytactin protein source, for people with other inborn errors of protein metabolism and for people with intractable epilepsy using ketogenic diet therapy. The company also offers a range of low protein functional foods for inborn errors of metabolism and a range of ketogenic diet therapy appropriate functional foods.